{"schema_version":"secwatch.filing_event.v1","accession":"0001125345-23-000077","form_type":"8-K","ticker":"MGNX","cik":"0001125345","company_name":"MACROGENICS INC","filed_at":"2023-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.006166+00:00","generated_at":"2026-06-15T08:10:23.762544+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"MacroGenics reports Q1 net loss $38M; cash runway through 2025 on $270M non-dilutive funding","bullets":["Net loss of $38.0M ($0.61 loss per share) vs. $66.4M loss year ago; revenue $24.5M (up 121% YoY).","Cash, equivalents & marketable securities $241.7M at March 31, 2023; additional $30M approval milestone from TZIELD received after Q1.","ZYNYZ (retifanlimab) approved by FDA for MCC; MacroGenics received $15M milestone, eligible for up to $650M more plus tiered royalties.","Sold TZIELD royalty interest to DRI for $100M upfront; retains 50% share above threshold and up to $430M in Sanofi milestones.","Phase 2 TAMARACK (vobra duo in mCRPC) enrollment under revised protocol to start Q2 2023; clinical update expected in 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001125345-23-000077","json":"https://secwatch.observer/filing/0001125345-23-000077.json","markdown":"https://secwatch.observer/filing/0001125345-23-000077.md","text":"https://secwatch.observer/filing/0001125345-23-000077.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1125345/000112534523000077/0001125345-23-000077-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1125345/000112534523000077/mgnx-20230509.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T08:10:23.762544+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}